Today: 9 June 2026
Adobe Stock Rises Before the Open as AI Selloff Faces a Fresh Test

Adobe Stock Rises Before the Open as AI Selloff Faces a Fresh Test

NEW YORK, May 19, 2026, 09:04 EDT

  • Adobe was up 2.14% in premarket trading at $261.10, after closing Monday at $255.64, up 3.25%.
  • Nasdaq regular trading was due to start at 9:30 a.m. ET; the exchange’s 2026 holiday list shows the next U.S. closure is Memorial Day on May 25.
  • The move came as S&P 500 and Nasdaq futures were lower, with technology shares still under pressure before the bell.

Adobe shares rose before the open on Tuesday, extending a rebound in a stock that has spent much of the year under pressure from fears that generative AI will eat into demand for traditional creative software. The shares were indicated at $261.10 in premarket trading, the early session before regular exchange hours, after closing Monday up 3.25%.

That matters now because the broader tape was not helping much. Futures tied to the S&P 500 and the tech-heavy Nasdaq were recently down 0.4% and 0.8%, respectively, as investors stayed wary of technology stocks and rising Treasury yields.

Adobe is still a damaged large-cap software name. Its market value stood near $103.33 billion, the stock traded at 14.90 times earnings, and its 52-week range ran from $224.13 to $422.95, leaving the shares well below last year’s high even after the latest bounce.

The latest support case rests partly on capital returns. Adobe said in April that its board approved a new $25 billion stock repurchase authorization through April 30, 2030; a repurchase, or buyback, is when a company buys its own shares to return cash and reduce share count over time. Chief Financial Officer Dan Durn called it a “direct expression of confidence” in cash flow. Adobe

The buyback did not end the argument. Reuters reported at the time that Adobe was trying to reassure investors as creative autonomous tools advanced, and noted pressure from Anthropic’s Claude Design and smaller design rivals such as Figma.

Adobe’s own numbers give bulls something to point to. In March, the company reported record first-quarter revenue of $6.40 billion, up 12% from a year earlier, and said AI-first annualized recurring revenue more than tripled. Annualized recurring revenue, or ARR, is a subscription metric that estimates recurring sales over a year.

Chief Executive Shantanu Narayen said Adobe had delivered “record Q1 results,” while Durn said subscription revenue rose 13% and operating cash flow reached a record $2.96 billion. The company also said Creative & Marketing Professionals subscription revenue rose 12% to $4.39 billion, and Business Professionals & Consumers subscription revenue rose 16% to $1.78 billion. Adobe

Analysts remain split. Oppenheimer analyst Brian Schwartz said Adobe’s “cadence of AI innovation” remained impressive after the company’s Summit event, but kept a Hold rating, citing competition and the risk that a new CEO could reset expectations. Stifel’s Parker Lane was more upbeat, saying “AI innovation was front and center” and assigning a Buy rating. TipRanks

But the rebound can still stall. Mizuho analyst Gregg Moskowitz downgraded Adobe to Neutral from Outperform in late April and cut his target to $270 from $315, writing that the firm had “wrongly held off” because valuation looked compelling and that risk/reward was now balanced. The downside case is plain enough: Adobe spends more to defend its franchise, AI-native tools keep taking attention, and revenue growth slows before AI products offset the damage. TheStreet

The next hard test is earnings. StockAnalysis lists Adobe’s next earnings date as June 11, and the market will be looking for cleaner evidence that Firefly, Acrobat AI and enterprise marketing tools are turning usage into paid demand, not just product headlines.

Stock Market Today

  • Designer Brands (DBI) Beats Q1 Earnings and Revenue Estimates
    June 9, 2026, 10:04 AM EDT. Designer Brands (DBI) reported Q1 earnings of $0.07 per share, surpassing the Zacks estimate of $0.02 and reversing a year-ago loss of $0.26. Revenue hit $696.35 million, just above the $696 million consensus. The company delivered a 250% earnings surprise and has beaten EPS estimates in four consecutive quarters. Shares rose about 19.5% year-to-date, outpacing the S&P 500's 8.2% gain. Despite strong results, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Retail - Apparel and Shoes sector ranks among the top three industries. Future stock performance will depend on management's outlook and upcoming earnings estimate revisions, with current consensus estimates at $0.30 EPS on $744 million revenue next quarter and $0.35 EPS on $2.91 billion revenue for the fiscal year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Wellgistics Health Doubles, WGRX Heads Into Key Test
Previous Story

Wellgistics Health Doubles, WGRX Heads Into Key Test

CoreWeave Shares Drop in Premarket as Google, Blackstone Shift AI Cloud Setup
Next Story

CoreWeave Shares Drop in Premarket as Google, Blackstone Shift AI Cloud Setup

Go toTop